中国妇幼健康研究
中國婦幼健康研究
중국부유건강연구
CHINESE JOURNAL OF MATERNAL AND CHILD HEALTH RESEARCH
2013年
6期
925-927
,共3页
儿童%肺大叶实变%重症支原体肺炎%匹多莫德%孟鲁司特%甲强龙
兒童%肺大葉實變%重癥支原體肺炎%匹多莫德%孟魯司特%甲彊龍
인동%폐대협실변%중증지원체폐염%필다막덕%맹로사특%갑강룡
children%lobar consolidation%severe mycoplasma pneumonia%pidotimod%montelukast%methylprednisolone
目的：探讨匹多莫德、孟鲁司特及甲强龙等药物联合治疗肺大叶实变性重症支原体肺炎的临床疗效。方法选择北京市昌平区中西医结合医院2010至2012年收治的60例肺大叶实变性重症支原体肺炎患儿，随机分为观察组和对照组。对照组给予阿奇霉素及常规止咳、化痰、退热等综合治疗，观察组在对照组的基础上，给予匹多莫德、孟鲁司特及甲强龙治疗。匹多莫德口服液每日2次，每次1支（400mg/支），连服2周，后改为每日1次，每次1支，总疗程为8周；孟鲁司特钠咀嚼片（2～5岁儿童给予4mg/片剂型，6～14岁儿童给予5mg/片剂型）每日1片，连用8周；每日1次静点甲基强的松龙2mg/kg，连用3天。8周后观察并比较两组患儿治疗总有效率和咳嗽持续时间、肺部实变影吸收时间、退热时间、住院时间和不良反应等情况。结果观察组治疗8周后总有效率为100．0％，对照组治疗8周后总有效率为80．0％，观察组总有效率明显高于对照组（χ2＝0．779，P＜0．01）。观察组在咳嗽持续时间、退热时间、住院时间方面相比对照组有明显缩短（观察组分别为6．8±2．2天、4．9±1．6天、8．5±1．7天；对照组分别为10．6±3．1天、8．2±1．8天、12．6±2．1天），经比较差异均具有统计学意义（ t值分别为-10．865、-11．439、-7．686，均P＜0．01）。结论匹多莫德、孟鲁司特及甲强龙联合阿奇霉素及其他常规对症治疗在治疗肺大叶实变性重症支原体肺炎方面疗效显著。
目的：探討匹多莫德、孟魯司特及甲彊龍等藥物聯閤治療肺大葉實變性重癥支原體肺炎的臨床療效。方法選擇北京市昌平區中西醫結閤醫院2010至2012年收治的60例肺大葉實變性重癥支原體肺炎患兒，隨機分為觀察組和對照組。對照組給予阿奇黴素及常規止咳、化痰、退熱等綜閤治療，觀察組在對照組的基礎上，給予匹多莫德、孟魯司特及甲彊龍治療。匹多莫德口服液每日2次，每次1支（400mg/支），連服2週，後改為每日1次，每次1支，總療程為8週；孟魯司特鈉咀嚼片（2～5歲兒童給予4mg/片劑型，6～14歲兒童給予5mg/片劑型）每日1片，連用8週；每日1次靜點甲基彊的鬆龍2mg/kg，連用3天。8週後觀察併比較兩組患兒治療總有效率和咳嗽持續時間、肺部實變影吸收時間、退熱時間、住院時間和不良反應等情況。結果觀察組治療8週後總有效率為100．0％，對照組治療8週後總有效率為80．0％，觀察組總有效率明顯高于對照組（χ2＝0．779，P＜0．01）。觀察組在咳嗽持續時間、退熱時間、住院時間方麵相比對照組有明顯縮短（觀察組分彆為6．8±2．2天、4．9±1．6天、8．5±1．7天；對照組分彆為10．6±3．1天、8．2±1．8天、12．6±2．1天），經比較差異均具有統計學意義（ t值分彆為-10．865、-11．439、-7．686，均P＜0．01）。結論匹多莫德、孟魯司特及甲彊龍聯閤阿奇黴素及其他常規對癥治療在治療肺大葉實變性重癥支原體肺炎方麵療效顯著。
목적：탐토필다막덕、맹로사특급갑강룡등약물연합치료폐대협실변성중증지원체폐염적림상료효。방법선택북경시창평구중서의결합의원2010지2012년수치적60례폐대협실변성중증지원체폐염환인，수궤분위관찰조화대조조。대조조급여아기매소급상규지해、화담、퇴열등종합치료，관찰조재대조조적기출상，급여필다막덕、맹로사특급갑강룡치료。필다막덕구복액매일2차，매차1지（400mg/지），련복2주，후개위매일1차，매차1지，총료정위8주；맹로사특납저작편（2～5세인동급여4mg/편제형，6～14세인동급여5mg/편제형）매일1편，련용8주；매일1차정점갑기강적송룡2mg/kg，련용3천。8주후관찰병비교량조환인치료총유효솔화해수지속시간、폐부실변영흡수시간、퇴열시간、주원시간화불량반응등정황。결과관찰조치료8주후총유효솔위100．0％，대조조치료8주후총유효솔위80．0％，관찰조총유효솔명현고우대조조（χ2＝0．779，P＜0．01）。관찰조재해수지속시간、퇴열시간、주원시간방면상비대조조유명현축단（관찰조분별위6．8±2．2천、4．9±1．6천、8．5±1．7천；대조조분별위10．6±3．1천、8．2±1．8천、12．6±2．1천），경비교차이균구유통계학의의（ t치분별위-10．865、-11．439、-7．686，균P＜0．01）。결론필다막덕、맹로사특급갑강룡연합아기매소급기타상규대증치료재치료폐대협실변성중증지원체폐염방면료효현저。
Objective To explore the clinical curative effect of drug combination therapy of pidotimod , montelukast , and methylprednisolone on severe mycoplasma pneumonia with lobar consolidation .Methods From 2010 to 2012 60 children diagnosed with severe mycoplasma pneumonia with lobar consolidation were admitted in Changping Hospital of Integrated Chinese and Western Medicine , and they were randomly divided into observation group and control group .The control group was given azithromycin and comprehensive treatment such as conventional suppressing cough , transforming phlegm and antifebrile , while the observation group was given pidotimod , montelukast and methylprednisolone therapy based on the therapy for the control group .Pidotimod was orally administrated with the dosage of 400mg twice a day for continuous 2 weeks.After that it was given 400mg once a day for continuous 6 weeks.One tablet of montelukast (4mg/tablet for children aged 2-5 and 5mg/tablet for children aged 6-14 ) was given once a day for continuous 8 weeks. Methylprednisolone (2mg/kg) was given by intravenous drip for 3 days.After 8 weeks of treatment two groups were compared in the aspects of total effective rate , cough duration , absorption of lung consolidation shadow , defervescence time , hospitalization stay and adverse reactions .Results The total effective rate of the observation group was 100%, which was significantly higher than that of the control group (80%) (χ2 =0.779,P<0.01) .The cough duration, defervescence time and hospitalization stay were evidently shorter in the observation group (6.8 ±2.2d, 4.9 ±1.6d, 8.5 ±1.7d for the observation group and 10.6 ±3.1d, 8.2 ±1.8d, 12.6 ±2.1d for the control group , respectively), and the differences were significant ( t value was -10.865, -11.439 and -7.686, respectively, all P <0.01). Conclusion The drug combination of pidotimod , montelukast and methylprednisolone with azithromycin and other conventional symptomatic treatment is very effective for severe mycoplasma pneumonia with lobar consolidation .
